Noemı́ Reguart
0000-0001-8190-499X
Publication & Citation Trends
Most Cited Works
Publications
410 total
Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer PDF
Cited by 416
OpenAlex
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study PDF
Cited by 265
OpenAlex
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ PDF
Cited by 548
OpenAlex
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study PDF
Cited by 244
OpenAlex
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer PDF
Cited by 244
OpenAlex
Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer PDF
Cited by 981
OpenAlex
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma
Cited by 469
OpenAlex
Association of<i>EGFR</i>L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial PDF
Cited by 235
OpenAlex
Research Topics
Lung Cancer Treatments and Mutations
(240)
Lung Cancer Research Studies
(78)
Cancer Immunotherapy and Biomarkers
(67)
Lung Cancer Diagnosis and Treatment
(65)
Cancer Genomics and Diagnostics
(64)
Frequent Co-Authors
Affiliations
Universidade da Coruña
University of Messina
Tongji University
Roche (Switzerland)
University of Verona